The Hemostatic effect of Badari Churna in excessive Menstrual Bleeding

Assesment of the hemostatic effect of Badari Churna (ZIZYPHUS SATIVUS ) in Asrugdara (Menorrhagia)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/01/049104

Enrollment

Registered

2023-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: The duration of bleeding must be > 7 days or quantity must be > 80 ml cycle or both.7 Patients with Uterine Fibroids , Adenomyosis , Endometriosis , Pelvic Inflammatory Disease. Patients fulfilling diagnostic criteria and patients complaining of previous history of Asrugdara for at least 2 consecutive cycle.

Exclusion criteria

Exclusion criteria: Patientâ??s suffering from severe Anemia. Suspected cases of spontaneous, threatened or incomplete abortion. Known cases of Diabetes Mellitus.

Design outcomes

Primary

Measure	Time frame
To asses the Hemostatic effict of Badari Churna (Zizyphus Sativus) as in the management of Asrugdara (Menorrhagia).Timepoint: Badari Churna will be given orally Schedule - Twice in a day Duration - 7 days Follow up - On 8th day of menses for 3 consecutive cycles	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Kalyani Borse

YMT Ayurvedic Medical College and Hospital.Sector 4, Kharghar, Navi Mumbai

drmangeshpatil21@gmail.com9324071592

Outcome results